Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia

Ann C. Skulas-Ray, Petar Alaupovic, Penny Margaret Kris-Etherton, Sheila Grace West

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.

Original languageEnglish (US)
Pages (from-to)360-367
Number of pages8
JournalJournal of Clinical Lipidology
Volume9
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Apolipoproteins
Hypertriglyceridemia
Omega-3 Fatty Acids
Eicosapentaenoic Acid
Docosahexaenoic Acids
Lipoproteins
Apolipoproteins B
Apolipoprotein C-III
1-Alkyl-2-acetylglycerophosphocholine Esterase
Placebos
Apolipoproteins C
VLDL Cholesterol
Apolipoprotein A-I
Apolipoproteins E
Atherosclerotic Plaques
Cross-Over Studies
Heparin
Triglycerides
Inflammation
Lipids

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

@article{a845173f33634debb0ce0aadd02d1eba,
title = "Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia",
abstract = "Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.",
author = "Skulas-Ray, {Ann C.} and Petar Alaupovic and Kris-Etherton, {Penny Margaret} and West, {Sheila Grace}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.jacl.2014.12.001",
language = "English (US)",
volume = "9",
pages = "360--367",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia

AU - Skulas-Ray, Ann C.

AU - Alaupovic, Petar

AU - Kris-Etherton, Penny Margaret

AU - West, Sheila Grace

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.

AB - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.

UR - http://www.scopus.com/inward/record.url?scp=84931562605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931562605&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2014.12.001

DO - 10.1016/j.jacl.2014.12.001

M3 - Article

VL - 9

SP - 360

EP - 367

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 3

ER -